Ionis and AstraZeneca’s WAINZUA gets EU approval for ATTRv-PN treatment
Ionis Pharmaceuticals (IONS) announced that Ionis and AstraZeneca’s (AZN) WAINZUA eplontersen has been approved in the European Union EU for ...
Pharmaceutical Technology on MSN3d
AstraZeneca and Ionis win EU approval for ATTR polyneuropathy
AstraZeneca and Ionis Pharmaceuticals’ polyneuropathy drug has won approval in the European Union (EU), where it will be ...
The Pharma Letter3d
EU nod next for ATTRv-PN drug
AstraZeneca and Ionis’ Wainzua (eplontersen) has been approved in the European Union (EU) for the treatment of hereditary ...
Zacks Investment Research on MSN2d
IONS/AZN Get FDA Nod for Amyloidosis Drug, Wainzua in Europe
Ionis Pharmaceuticals IONS announced that the European Commission (“EC”) has approved Wainzua (eplontersen) for treating ...
Business Wire3d
WAINZUA (eplontersen) approved in the EU for the treatment of hereditary transthyretin-mediated amyloidosis in adults with stage 1 or stage 2 polyneuropathy
WAINZUA is the only approved medicine in the EU for the treatment of ATTRv-PN that can be self-administered monthly via an auto-injector. The approval by the European Commission (EC) follows the ...
Nasdaq3d
Ionis Pharma Reports Approval Of WAINZUA In The EU - Quick Facts
WAINZUA is the only approved medicine in the EU for the treatment of ATTRv-PN. WAINZUA was approved under the brand name WAINUA for the treatment of ATTRv-PN in the U.S. in December 2023 and has ...
NTLA's Q4 Loss Narrower Than Estimates, Revenues Increase Y/Y
Intellia reports better-than-expected fourth-quarter 2024 results. The company provides updates on its pipeline candidates.
Nasdaq2d
IONS/AZN Get FDA Nod for Amyloidosis Drug, Wainzua in Europe
Ionis Pharmaceuticals IONS announced that the European Commission (“EC”) has approved Wainzua (eplontersen) for treating adult patients with hereditary transthyretin-mediated amyloidosis with ...